EGFR and non-small cell lung carcinoma: There was significant heterogeneity in the T790M mutation subgroup when analyzing ORR, DCR, and grade 3 AEs between Osimertinib and EGFR-TKIs/chemotherapy, and further studies with more focus on Osimertinib treatment in advanced NSCLC patients with T790M mutation-positive tumors are therefore suggested.